- General Drug Summary
- Description
- An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake. [PubChem]
- Categories
- Vitamin B Complex
- Structure
- Summary In Neonatal Jaundice
-
2 record(s) for Nicotinamide NA in Neonatal Jaundice.
- PMID
- Drug Name
- Efficacy
- Evidence
- 1772116
- Nicotinamide
- NA
- Review
- Summary
- Sometimes known as vitamin B5.
- In vitro and in vivo characteristics of a heme oxygenase inhibitor: ZnBG. The American journal of the medical sciences, 1991 Dec [Go to PubMed]
- The authors evaluated the in vitro and in vivo efficacy and photosensitizing effects of zinc deuteroporphyrin 2,4-bis glycol (ZnBG) as an inhibitor of adult Wistar rat tissue heme oxygenase (HO) activity and bilirubin production. Concentrations of 0.02-0.05 microM ZnBG inhibited the HO activity in postmitochondrial supernatants of liver, spleen, brain, and kidney by at least 50%. Administration of 4 mumole ZnBG/kg body weight to adult rats significantly reduced the total body carbon monoxide (CO) excretion, an index of bilirubin formation, from 1 to 6 hours posttreatment. At 6 hours posttreatment, the HO activity in postmitochondrial supernatants of the liver and spleen, but not of the brain, was significantly lowered. ZnBG also behaved as an in vitro photooxidizer by degrading, in the presence of cool white light, the reduced form of nicotinamide adenine dinucleotide phosphate and histidine to CO and other nonidentified products. ZnBG also enhanced the natural photodegradation of bilirubin. Furthermore, admnistration of ZnBG to 1-day-old neonatal rats caused mortality within 12 hours in light-exposed animals, with a lethal dose 50 of 23 microM/kg body weight.
- 12956017
- Nicotinamide
- NA
- Review
- Summary
- Glucose-6-phosphate dehydrogenase (G-6-PD) is an enzyme in the first step of the hexose-monophosphate shunt required for the generation of nicotinamide adenine dinucleotide phosphate (NADPH). G-6-PD activity is low in a number of jaundiced patients.
- Glucose-6-phosphate dehydrogenase (G-6-PD) levels in jaundiced neonates in Calabar. Nigerian journal of medicine : journal of the Nati, [Go to PubMed]
- Glucose-6-phosphate dehydrogenase (G-6-PD) is an enzyme in the first step of the hexose-monophosphate shunt required for the generation of nicotinamide adenine dinucleotide phosphate (NADPH). Red blood cells of neonates with deficient G-6-PD are potentially susceptible to acute severe haemolysis and may result in haemolytic jaundice. This study was to determine the association between neonatal jaundice and G-6-PD activity and the degree of deficiency of this enzyme among the affected neonates.
G-6-PD levels in jaundiced neonates admitted into the Special Care Baby Unit (SCBU) of the University of Calabar Teaching Hospital were assayed between May 2000 and April 2001 using Biotic (London) diagnostic assay kit method. Data was analyzed using SPSS (base 705) data Editor (Microsoft Windows 95).
A total of 102 jaundiced neonates between ages 1 and 10 days were studied. Out of the 102 jaundiced neonates, 39 (38.2%) were G-6-PD deficient with G-6-PD concentration of 48.89 +/- 72 mU/10(12) erythrocyte compared to 129.51 +/- 0.92 mU/10(12) erythrocyte in the remaining 63 subjects. The prevalence rate of G-6-PD deficiency among jaundiced neonates was 38% which is significantly high (p < 0.05) considering the study sample size. There was no significant difference (p > 0.05) in G-6-PD level in the males and females.
G-6-PD activity is low in a number of jaundiced patients. Routine assay of G-6-PD in jaundiced patients is recommended.